Emiliano Calvo
About
Emiliano Calvo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Emiliano Calvo has authored 340 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Oncology, 122 papers in Pulmonary and Respiratory Medicine and 109 papers in Molecular Biology. Recurrent topics in Emiliano Calvo's work include Cancer Immunotherapy and Biomarkers (89 papers), CAR-T cell therapy research (48 papers) and Lung Cancer Treatments and Mutations (44 papers). Emiliano Calvo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (89 papers), CAR-T cell therapy research (48 papers) and Lung Cancer Treatments and Mutations (44 papers). Emiliano Calvo collaborates with scholars based in Spain, United States and France. Emiliano Calvo's co-authors include Maria J. de Miguel, Víctor Moreno, Paolo A. Ascierto, Filippo de Braud, Margaret K. Callahan, Patrick A. Ott, Padmanee Sharma, Josep Tabernero, Dung T. Le and José Baselga and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Emiliano Calvo
330 papers receiving 9.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Emiliano Calvo Spain | 45 | 6.0k | 3.1k | 2.7k | 1.7k | 1.5k | 340 | 9.3k | ||
| Jean‐Pierre Delord France | 43 | 5.5k 0.9× | 2.2k 0.7× | 2.0k 0.7× | 1.7k 1.0× | 1.1k 0.7× | 260 | 8.4k | ||
| Christophe Le Tourneau France | 46 | 4.9k 0.8× | 2.1k 0.7× | 2.3k 0.8× | 1.3k 0.7× | 1.3k 0.9× | 335 | 8.7k | ||
| Tanguy Y. Seiwert United States | 43 | 7.0k 1.2× | 2.9k 0.9× | 3.8k 1.4× | 2.5k 1.4× | 1.9k 1.3× | 228 | 11.1k | ||
| Zev A. Wainberg United States | 51 | 6.2k 1.0× | 2.8k 0.9× | 3.2k 1.2× | 1.3k 0.7× | 2.1k 1.4× | 343 | 9.8k | ||
| Joseph P. Eder United States | 47 | 8.2k 1.4× | 3.4k 1.1× | 3.2k 1.2× | 2.9k 1.7× | 1.6k 1.1× | 178 | 12.2k | ||
| Laura Q.M. Chow United States | 44 | 9.1k 1.5× | 2.9k 0.9× | 4.6k 1.7× | 3.0k 1.7× | 1.3k 0.9× | 159 | 12.4k | ||
| Alain C. Mita United States | 46 | 3.4k 0.6× | 3.7k 1.2× | 1.8k 0.7× | 837 0.5× | 1.3k 0.8× | 210 | 8.1k | ||
| Vanna Chiarion‐Sileni Italy | 51 | 7.3k 1.2× | 4.1k 1.3× | 2.2k 0.8× | 3.1k 1.8× | 1.0k 0.7× | 244 | 10.4k | ||
| E. Gabriela Chiorean United States | 42 | 4.7k 0.8× | 2.1k 0.7× | 1.5k 0.6× | 1.7k 1.0× | 809 0.5× | 209 | 7.1k | ||
| Marcia S. Brose United States | 44 | 4.5k 0.8× | 3.6k 1.2× | 2.1k 0.8× | 694 0.4× | 1.1k 0.7× | 187 | 11.5k |
Countries citing papers authored by Emiliano Calvo
Since
Specialization
Citations
This map shows the geographic impact of Emiliano Calvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emiliano Calvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emiliano Calvo more than expected).
Fields of papers citing papers by Emiliano Calvo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emiliano Calvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emiliano Calvo. The network helps show where Emiliano Calvo may publish in the future.
Co-authorship network of co-authors of Emiliano Calvo
This figure shows the co-authorship network connecting the top 25 collaborators of Emiliano Calvo. A scholar is included among the top collaborators of Emiliano Calvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emiliano Calvo. Emiliano Calvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moreno, Irene, Cristina Nieto‐Jiménez, Bernard Doger, et al.. (2024). Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. International Journal of Molecular Sciences. 25(4). 2222–2222.
2.
Nieto‐Jiménez, Cristina, Balázs Győrffy, Víctor Moreno, et al.. (2024). In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies. International Journal of Molecular Sciences. 25(7). 3987–3987.
3.
Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521.
4.
Melero, Ignacio, Maria J. de Miguel, Guillermo de Velasco, et al.. (2024). Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.. Journal of Clinical Oncology. 42(16_suppl). 2513–2513.
5.
D’Alise, Anna Morena, Guido Leoni, Gabriella Cotugno, et al.. (2024). Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. Clinical Cancer Research. 30(11). 2412–2423.
6.
Aggen, David H., David S. Hong, Jeffrey Clarke, et al.. (2023). Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). 517–517.
7.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554.
8.
Doger, Bernard, Cristina Nieto‐Jiménez, Víctor Moreno, et al.. (2023). Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities. Cancers. 15(12). 3250–3250.
9.
Moore, Kathleen N., Adam Asch, Víctor Moreno, et al.. (2022). 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A472–A473.
10.
Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178.
11.
Maitland, Michael L., Jasgit C. Sachdev, Manish Sharma, et al.. (2021). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research. 27(16). 4511–4520.
12.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251.
13.
Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897.
14.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616.
15.
Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185.
16.
Azaro, Analía, Jordi Rodón, Antonio Calles, et al.. (2015). A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs. 33(3). 710–719.
17.
Goldman, Jonathan H., Sabine Eckhardt, Mitesh J. Borad, et al.. (2014). Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(5). 1002–1009.
18.
Rodón, Jordi, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez, et al.. (2014). First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research. 21(3). 553–560.
19.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261.
20.
White, Dorothy A., Philippe Camus, Masahiro Endo, et al.. (2010). Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. American Journal of Respiratory and Critical Care Medicine. 182(3). 396–403.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean‐Pierre Delord Breakdown of academic impact, for papers by Christophe Le Tourneau Breakdown of academic impact, for papers by Tanguy Y. Seiwert Breakdown of academic impact, for papers by Zev A. Wainberg Breakdown of academic impact, for papers by Joseph P. Eder Breakdown of academic impact, for papers by Laura Q.M. Chow Breakdown of academic impact, for papers by Alain C. Mita Breakdown of academic impact, for papers by Vanna Chiarion‐Sileni Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Marcia S. Brose